Target intelligence / Profile preview

Borrelia burgdorferi outer surface protein A (OspA) (OspA)

Target
OspA
Molecular classification
Lipoprotein, Bacterial surface protein, Antigen
01

Overview

Borrelia burgdorferi outer surface protein A (OspA) is a major surface-exposed lipoprotein of the spirochete that causes Lyme disease (UniProt: P0CL66). It is predominantly expressed when the bacteria are in the midgut of the Ixodes tick vector, where it mediates attachment to the tick gut protein TROSPA (PubMed: 15210926). Related antigens such as OspB and OspC also play roles in the bacterial life cycle, with OspC being essential for mammalian infection (PubMed: 15731211). During the tick's blood meal, OspA is downregulated as the bacteria migrate to the salivary glands and upregulate OspC for transmission to the mammalian host (PubMed: 10376650). Because OspA is present in the tick but largely absent in the host during early infection, it serves as a unique target for transmission-blocking vaccines. These vaccines work by inducing antibodies in the human host that are ingested by the tick during a blood meal, neutralizing the bacteria before they can be transmitted (CDC: Lyme Disease Vaccine). While the first human OspA vaccine, LYMErix, was withdrawn due to concerns over potential autoimmune cross-reactivity, newer multivalent candidates like VLA15 are designed to protect against multiple Borrelia species and strains by targeting various OspA serotypes (ClinicalTrials.gov: NCT04050917).

Other names
Outer surface protein AOspABBA15Borrelial lipoprotein OspAOuter surface protein B (OspB)Outer surface protein C (OspC)VlsE
02

Mechanism of action

Induction of host antibodies that neutralize Borrelia burgdorferi within the tick midgut during a blood meal, preventing transmission to the mammalian host.

03

Biological functions

Bacterial adhesionTick midgut attachmentImmune responseImmune evasion
04

Disease associations

InfectionLyme disease
05

Safety considerations

Historical association with treatment-resistant Lyme arthritis (OspA-HLA-DR4 cross-reactivity)Injection site reactionsLimited protection against different Borrelia strains
06

Interacting drugs

LYMErix

2 more in the full profile.

07

Biomarkers

Anti-OspA IgG antibody titer

Beyond the preview

Go deeper on Borrelia burgdorferi outer surface protein A (OspA) (OspA).

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Drug pipeline

Full profile access

Explore the programs pursuing this target and their development progress.

  • Drug candidates
  • Developers
  • Development stage

Clinical trials

Full profile access

Follow the clinical studies evaluating therapies directed at this target.

  • Trial design
  • Status
  • Readouts

Competitive landscape

Full profile access

Compare approaches across drug candidates, modalities, and indications.

  • Programs
  • Modalities
  • Indications

Literature & evidence

Full profile access

Investigate the research and source evidence behind target biology and development.

  • Publications
  • Sources
  • Analysis

Patents

Full profile access

Explore patent activity around therapies and technologies addressing this target.

  • Patents
  • Assignees
  • Technologies

Research & analysis

Full profile access

Connect target biology, drug development, and emerging evidence in your research.

  • Biology
  • Development news
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on Borrelia burgdorferi outer surface protein A (OspA) (OspA).

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call